Crispr
Researchers repurpose a DNA-shredding CRISPR enzyme to target cancer cells 0ARPA-H commits up to $160 million to custom gene editing for rare diseases 0FDA clears Casgevy gene therapy for children as young as two with sickle cell disease 0Base editing in human embryos advances, but mosaicism limits its use 0Base editing of human embryos sharpens precision and revives ethical debate 0